Exhibit 10.14

 

NOTE: Portions of this Exhibit are the subject of a Confidential Treatment
Request by the Registrant to the Securities and Exchange Commission. Such
portions have been redacted and are marked with a "[*]" in place of the redacted
language.

 

 

 

FIRST AMENDMENT TO

RESEARCH FUNDING AGREEMENT

 

                This is the First Amendment to the Research Funding Agreement
(the “Agreement”) between Sangamo BioSciences, Inc. (“Sangamo”) and Baxter
Healthcare Corporation (“Baxter”), dated January 11, 2000.  This First Amendment
shall be effective as of November 14, 2002.

 

RECITALS

 

                WHEREAS, the Agreement was assigned by Baxter to Edwards
Lifesciences LLC (“Edwards”) pursuant to a Reorganization Agreement between
Baxter International Inc. and Edwards Lifesciences Corporation dated March 31,
2000; and

 

                NOW, THEREFORE, for good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Agreement is hereby amended
as follows:

 

1.             Every occurrence of “Baxter Healthcare Corporation” in the
Agreement shall be replaced with “Edwards Lifesciences LLC” and every occurrence
of “Baxter” shall be replaced with “Edwards”.

 

2.             The term of the Agreement set forth in Paragraph 4.1 shall be
extended to December 31, 2003.

 

3.             EDWARDS agrees to pay SANGAMO on or before November 30, 2002 an
additional One Million Nine Hundred Fifty Thousand Dollars ($1,950,000) for the
research activities set forth on Exhibit A performed during 2002.

 

--------------------------------------------------------------------------------

 

4.             EDWARDS agrees to pay SANGAMO an additional One Million Dollars
($1,000,000), payable in four equal installments at the beginning of each
calendar quarter, beginning on January 1, 2003, to complete the research
activities set forth on new Exhibit B attached hereto and new Exhibit C attached
hereto.

5.             The parties agree that this First Amendment *** with respect to
the research activities to be performed and the amount of funding to be paid
under this Agreement.

 

6.             The Agreement, as amended in this First Amendment, together with
the License Agreement between SANGAMO and EDWARDS dated January 11, 2000, as
amended in the First and Second Amendments thereto, represent the entire
agreement between the parties with respect to its subject matter and supersede
all prior agreements and understandings between the parties.

 

7.             All other terms and conditions shall remain the same.

 

EDWARDS LIFESCIENCES LLC

 

SANGAMO BIOSCIENCES, INC.

 

 

 

 

 

 

/s/ JOHN KEHL

 

/s/ EDWARD LANPHIER

 

 

 

Name:

John Kehl

 

Name:

Edward Lanphier

 

 

 

 

 

Title:

Corporate Vice President

 

Title:

President & CEO

 

 

 

 

 

Date:

November 15, 2002

 

Date:

November 18, 2002

 

--------------------------------------------------------------------------------

***Certain information on this page has been omitted and filed separately with
the Commission pursuant to a request for Confidential Treatment.

 

2

--------------------------------------------------------------------------------

 

Exhibit B to Research Funding Agreement

(Amended Schedule 2 to License Agreement)

 

 

***

 

 

--------------------------------------------------------------------------------

***Certain information on this page has been omitted and filed separately with
the Commission pursuant to a request for Confidential Treatment.

 

3

--------------------------------------------------------------------------------

 

Exhibit C to Research Funding Agreement

(Schedule 3 to License Agreement)

 

 

***

 

 

--------------------------------------------------------------------------------

***Certain information on this page has been omitted and filed separately with
the Commission pursuant to a request for Confidential Treatment.

 

4

--------------------------------------------------------------------------------